Diagnostyka S.a. · GPW:DIA
Diagnostyka — Q1 2025 Earnings Presentation
18 slides from Diagnostyka's earnings presentation, May 28, 2025
Slide 1: Financial results of the Diagnostyka Group for Q1 2025
Financial results of the Diagnostyka Group for Q1 2025 28 May 2025
Slide 2: Presenters
Presenters: Jakub Swadźba Paweł Chytła President of the Management Board, Vice President of the Management Board, Chief Executive Officer (CEO) Chief Financial Officer (CFO)
Slide 3: Q1 2025 operational highlights
Q1 2025 operational highlights
Slide 4: Q1 2025 summary
Q1 2025 summary Financial highlights Operational highlights Diagnostic tests Group’s revenue 40 PLUS Two bolt-on volume preventive-screening PLN 594.9 m programme material acquisitions 45.2 m (+22.5% yoy) contribution to in laboratory (+8.3% yoy) diagnostics diagnostic tests volumes Net profit attri
Slide 5: Financial results
Financial results
Slide 6: Growth in revenue from contracts with customers
Growth in revenue from contracts with customers Revenue from contracts Contribution Diagnostic tests volume (million) Contribution with customers (PLN million) to revenue to diagnostic tests volume: + Higher revenue from contracts with customers was B2C +23.1% yoy mainly attributable to organic grow
Slide 7: Increase in operating expenses
Increase in operating expenses Operating expenses (PLN million) Increase in operating + In Q1 2025, operating expenses rose faster year on year than revenue from contracts expenses (%): 24.2% with customers. Growth in revenue from contracts with customers (%): 23.1% + Personnel expenses, raw materia
Slide 8: Recurring EBITDA at PLN 161.2 million, up 18.2% yoy
Recurring EBITDA at PLN 161.2million, up 18.2% yoy Recurring EBITDA (PLN million) Recurring EBITDA 28.4% 27.3% margin (%): + Recurring EBITDA margin contracted by 1.1 pp yoy to 27.3% in +18.2% yoy Q1 2025, yet remained above the full-year 2024 level of 26.1%. 161.2 + The margin compression was chief
Slide 9: Net profit growth yoy
Net profit growth yoy Change Change Q1 2024 Q1 2025 yoy (%) yoy Key drivers of net profit growth in Q1 2025: Recurring EBITDA 136.4 161.2 24.8 18.2% Recurring EBITDA margin 28.4% 27.3% -1.1% + The principal driver of Q1 2025 net-profit growth was a robust 18.2 % yoy increase in Recurring One-off cos
Slide 10: Robust cash flow supporting the Group's further growth
Robust cash flow supporting the Group's further growth Free cash flow (PLN million) Cash Q1 2024–Q1 2025 (PLN million) FCF1/EBITDA: 77.4% 81.7% 294.9 328.4 130.1 105.0 Q1 2024 Q1 2025 159.3 -14.1 130.1 -15.1 Capex (PLN million) 96.7 Capex excl. M&A/revenue2: 7.6% 5.5% -32.5 -0.9 -7.5 -36.1 43.2 6.9
Slide 11: Net debt and working capital
Net debt and working capital + Net working capital rose to PLN 197.5 million, driven mainly by a PLN 74.5 million increase in trade receivables. + Days Inventory Outstanding (DIO) and Days Payable Outstanding (DPO) were broadly unchanged from Q1 2024, whereas Days Sales Outstanding (DSO) edged up sl
Slide 12: Group's 2025 Outlook
Group’s 2025 Outlook + Average selling-price growth underpinned by a favourable product mix and the commenced consolidation of DI businesses + Steady volume growth supported by favourable market trends + Termination of the 40 PLUS preventive-screening programme (April 2025) + Continued M&A activity
Slide 13: Q&A
Q&A
Slide 14: Appendices
Diagno Appendices
Slide 15: Statement of profit or loss
1 Jan–31 Mar 2025 (unaudit- 1 Jan–31 Mar 2024 (unaudit- Statement of profit or loss (thou. PLN) ed) ed) Revenue 594,850 485,484 Revenue from contracts with customers 591,552 480,471 Other income 3,298 5,013 Operating expenses -482,620 -388,739 Depreciation and amortisation -47,083 -38,902 Raw materi
Slide 16: Appendix: Assets and equity and liabilities
Appendix Assets (thou. PLN) As at 31 Mar 2025 (unaudit- ed) As at 31 Dec 2024 Equity and liabilities (thou. PLN) As at 31 Mar 2025 (unaudit- ed) As at 31 Dec 2024 Non-current assets 1,426,613 1,390,996 Equity 509,118 433,499 Property, plant and equipment 425,992 422,400 Share capital 33,757 33,757 R
Slide 17: Appendix: Cash flow
Appendix Cash flow (thou. PLN) 1 Jan–31 Mar 2025 (unaudit- ed) 1 Jan–31 Mar 2024 (unaudit- ed) 1 Jan–31 Mar 2025 (unaudit- ed) 1 Jan–31 Mar 2024 (unaudit- ed) Net cash from operating activities Cash flows from investing activities Profit (loss) before tax 97,144 86,924 Proceeds from sale of property
Slide 18: Contact
Contact Michał Błasiński Investor Relations Director michal.blasinski@diag.pl Disclaimer This presentation has been prepared by Diagnostyka S.A. (the “Company”) for its shareholders, analysts, and other stakeholders. It is intended for informational purposes only and does not constitute an offer, or